Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesImmunic Inc

Immunic Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
7.7966 USD -0.32 ( 3.98%)
Last update at 2026-11-12T15:44:00Z
VOLUME
47956
Market Cap
112.60M

Momentum Score

…

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.50
Low
8.11
High
52 Week Price Range
0.94
Low
3.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Immunic Inc is a clinical-stage biopharmaceutical company developing oral small-molecule immunomodulators for chronic inflammatory and autoimmune diseases, with lead programs advancing through clinical development. Long-term growth depends on successful trial outcomes, regulatory approvals and adoption of oral therapies to address unmet needs, which could support future revenue and partnerships. Investors may find the company attractive for exposure to potential value creation from clinical milestones.

Principal risks include clinical and regulatory setbacks, absence of approved products and meaningful revenue, reliance on external financing, and intense competition in autoimmune drug development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.12
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.05
ROE
-112.05%
Net Debt
-45.34M
ROCE
-404.09%
Diluted EPS TTM
-1.83

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -120.41M -92.94M -44.02M -34.93M -41.48M
Net income -154.30M -92.79M -43.96M -34.83M -41.48M
Selling general administrative 15.26M 13.30M 10.33M 14.52M 13.59M
Reconciled depreciation 0.08M 0.09M 0.04M 0.05M 0.73M
Ebit -119.49M -91.75M -48.97M -37.03M -34.80M
Ebitda -53.55M -91.67M -48.93M -36.98M -34.07M
Depreciation and amortization 65.94M 0.09M 0.04M 0.05M 0.73M
Non operating income net other -0.92M -1.28M 4.95M 2.10M 0.55M
Operating income -119.49M -91.67M -48.97M -37.03M -42.02M
Other operating expenses 86.52M 91.67M 48.97M 37.03M 38.41M
Interest expense 1.04M 0.09M 0.06M 0.11M 0.00M
Interest income 1.04M 0.07M 0.06M 0.11M 0.52M
Net interest income 1.04M 0.07M 0.06M 0.11M 0.52M
Non recurring 32.97M - - - -1.22M
Income tax expense 33.89M -0.15M -0.06M -0.11M 0.55M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 86.52M 91.67M 48.97M 37.03M 38.41M
Total other income expense net -0.92M -1.28M 4.95M 2.10M -3.59M
Net income from continuing ops -120.41M -92.94M -44.02M -34.93M -41.48M
Net income applicable to common shares -120.41M -92.94M -44.02M -34.93M -41.48M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 54.30M 127.75M 139.10M 167.86M 65.95M
Other current assets 5.16M 9.49M 18.12M 1.23M 2.86M
Total liab 25.37M 14.07M 11.98M 9.08M 7.59M
Total stockholder equity 28.93M 113.68M 127.11M 158.78M 58.36M
Other current liab 18.93M 8.22M 0.58M 4.70M 0.34M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -410.89M -317.28M -196.87M -103.93M -59.91M
Good will - 0.00M 32.97M 32.97M 32.97M
Other assets - 0.04M 0.04M 0.94M 0.04M
Cash 46.67M 106.75M 86.86M 127.45M 29.37M
Total current liabilities 24.73M 13.08M 11.40M 8.40M 7.07M
Current deferred revenue - - 6.66M - 1.01M
Net debt -45.34M -105.18M -86.28M -126.77M -28.85M
Short term debt 0.69M 0.57M 0.41M 0.53M 3.30M
Short long term debt total 1.33M 1.56M 0.58M 0.68M 0.52M
Other stockholder equity 436.06M 427.93M 324.24M 266.82M 53.69M
Property plant equipment - 0.29M 1.10M 0.20M 0.08M
Total current assets 52.53M 125.86M 104.99M 133.75M 32.23M
Net tangible assets - 113.68M 94.14M 125.81M 25.39M
Short term investments 0.00M 9.63M - - -
Net receivables 0.70M 2.66M 2.15M 1.64M 0.76M
Inventory - -2.66M -2.15M 3.42M -
Accounts payable 5.10M 4.28M 3.75M 3.70M 2.42M
Accumulated other comprehensive income 3.76M 3.04M -0.25M -4.11M -1.37M
Common stock total equity - 0.00M 0.00M 0.00M 0.00M
Retained earnings total equity - -317.28M -196.87M -103.93M -59.91M
Non currrent assets other - 0.04M 0.04M 0.04M 0.04M
Non current assets total 1.76M 1.89M 34.11M 34.12M 33.73M
Capital lease obligations 1.33M 1.56M 0.58M 0.68M 0.52M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -9.74M -0.07M -0.15M 10.54M -0.41M
Change to liabilities 2.04M 3.52M 0.41M 0.86M -7.77M
Total cashflows from investing activities -9.74M -0.07M -0.15M 10.54M -0.41M
Total cash from financing activities 95.76M 42.84M 144.43M 34.90M 0.00M
Change to operating activities 8.73M -9.46M -3.37M -0.90M 0.59M
Net income -120.41M -92.94M -44.02M -34.93M -41.48M
Change in cash 19.88M -40.59M 98.08M 16.30M -43.58M
Begin period cash flow 86.86M 127.45M 29.37M 13.07M 56.90M
End period cash flow 106.75M 86.86M 127.45M 29.37M 13.32M
Total cash from operating activities -65.14M -83.23M -46.12M -28.55M -43.16M
Issuance of capital stock 95.57M 42.75M 144.43M 35.16M 0.00M
Depreciation 0.08M 0.09M 0.04M 0.05M 0.73M
Other cashflows from investing activities - - - 10.59M 0.18M
Sale purchase of stock 0.18M 0.09M 144.43M 34.90M 0.00M
Other cashflows from financing activities 0.01M -0.07M -0.15M -0.27M -0.11M
Change to netincome 45.66M 18.91M 0.22M 7.70M 5.19M
Capital expenditures 0.11M 0.07M 0.15M 0.06M 0.60M
Cash flows other operating 7.49M -12.80M -2.78M -2.22M 0.17M
Exchange rate changes - - - - -0.00M
Cash and cash equivalents changes 20.88M -40.46M 98.16M 16.89M -43.58M
Change in working capital 9.53M -9.28M -2.37M -1.36M -7.61M
Stock based compensation 7.93M 5.95M 2.75M 6.51M 3.74M
Other non cash items 37.73M 8.62M -2.53M 1.54M 0.23M
Free cash flow -65.26M -83.30M -46.27M -28.60M -43.76M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
IMUX
Immunic Inc		 -0.32
3.98%		 7.80 - - - 4.48 -0.85
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Immunic Inc

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

1200 Avenue of the Americas, New York, NY, United States, 10036

332 255 9818

https://imux.com

80

Name Title Year Born
Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A Exec. Chairman 1971
Dr. Daniel Vitt CEO, Pres & Director 1968
Mr. Glenn Whaley CPA Chief Financial Officer 1968
Dr. Andreas Muehler M.D., Ph.D. Chief Medical Officer 1964
Dr. Hella Kohlhof Chief Scientific Officer 1973
Jessica Breu Head of Investor Relations & Communications NA
Mr. Inderpal Singh Gen. Counsel 1966
Mr. Patrick Walsh Chief Bus. Officer 1983
Dr. Duane D. Nash J.D., M.B.A., M.D. Executive Chairman 1971
Dr. Daniel Vitt Ph.D. CEO, President & Director 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…